Administration Information. Entrust may store information in and related to Customer’s Order and Management Account and information generated by Customer’s usage of the Hosted Service, such as Customer’s access credentials, contact information for Agents, and entitlement consumption (“Administration Information”) in the United States and/or Canada, and may process Administration Information for the purposes of billing, providing Support and to investigate fraud, abuse or violations of this Agreement in the United States, Canada and other locations where Entrust maintains its support and investigation personnel.
Administration Information. Long-term If patients need pre-treatment with nebulised salbutamol 2.5mg, this can be mixed directly with colistin (immediately prior to use) and nebulised. Reference: Xxxxxxx XX, Xxxxxxx NR, Xxxxxxxx XX (1992) Cystic Fibrosis Inhalation Therapy: Stability of a Combined Salbutamol/Colistin Solution. Australian Journal of Hospital Pharmacy. 22(5):378-80 Baseline assessment and ongoing monitoring – by Specialist Initial specialist monitoring: • Spirometry pre and post the initial (test) dose. Ongoing specialist monitoring: • Sputum microbiology GP / Community Team or other Primary Care monitoring responsibilities • On-going compliance and tolerance Consultant / Specialist prescribing responsibilities • Administration of the first (test) dose with lung function monitoring • Training the patient/carer in use of nebulised antibiotics • Prescription and supply (via hospital pharmacy) of the first month of colistin and diluents • Supply and ongoing maintenance of an appropriate nebuliser/compressor system • On-going supply of plastic syringes to measure diluent volumes • Assess response to treatment and to discontinue if no benefit • Ongoing clinical and microbiological review GP prescribing responsibilities • On-going prescription of colistin and diluents (in plastic ampoules) Additional Information • Diluents Diluents must be supplied in 5ml plastic ampoules for ease of use and to avoid the risks associated with breaking glass ampoules. Where part ampoules need to be used, volumes do not need to be measured accurately using a syringe, they can be estimated from the original volume in the vial. Recommended method of reconstitution: The method used for the test dose should be continued. Any change in the diluents used will require the test dose to be repeated. o Method 1: 5ml sodium chloride 0.9% o Method 2: 2ml water + 2ml sodium chloride 0.9% (least likely to cause bronchoconstriction) • Nebuliser and associated equipment (Pari LC or eFlow) This will be supplied by the hospital, and will be serviced / replaced when required. • Expiratory filters These are used while patients are in hospital to minimise risks of antibiotic resistance and staff sensitisation due to repeated exposure. At home the use of expiratory filters is not considered to be necessary provided the patient nebulises alone in a well ventilated room. If a particular patient wants to use filters they may be purchased direct from PARI Medical Limited. It is recommended that pets are not present in ...
Administration Information. 1. AWARD
Administration Information. If measuring ciclosporin trough levels, ask the patient to omit morning dose of ciclosporin. • Levels not needed for dermatological doses but may be indicated to check for toxicity. There is no correlation between efficacy of treatment in psoriasis and serum levels of ciclosporin. Duration of therapy / How the treatment will be reviewed and if appropriate, stopped • Indefinite as long as efficacy and safety profiles are maintained. • Licensed for 8 weeks’ use in atopic dermatitis in patients aged over 16 years. Baseline assessment and ongoing monitoring – by Specialist • Check FBC, eGFR, ALT and albumin, BP and glucose, every 2 weeks, until a stable dose has been achieved for 6 weeks. • Watch creatinine if a NSAID is added (particularly diclofenac). GP / Community Team or other Primary Care monitoring responsibilities Report any suspected adverse drug reactions to the hospital specialist. Once the patient has been on a stable dose for 6 weeks: • check FBC, eGFR, ALT and albumin, BP and glucose every month for 3 months. Where there is a low risk of toxicity, onward monitoring may then be reduced to 3-monthly as a minimum, after discussion with the relevant consultant, and usually not in children or those at high risk of toxicity, with renal impairment. Risk factors for toxicity include: a history of adverse drug events; medical co-morbidities including renal and liver impairment (e.g. NAFLD) and malignancy; patients at the extremes of weight (BMI <18 or >30 kg/m2); old age (>80 years). Patients on concomitant DMARDs, especially leflunomide, should have monthly monitoring. Be aware that creatinine may increase if NSAID is added (particularly diclofenac). • Check blood pressure as above and act on abnormal readings If BP cannot be controlled, stop ciclosporin. Consultant / Specialist prescribing responsibilities • Rheumatology / Dermatology medical team are responsible for the initiation and six weeks’ prescription of ciclosporin at a stable dose. • Patient education will be undertaken within the Rheumatology/Dermatology multidisciplinary team. Pregnancy testing / contraceptive cover to be checked. • Advice regarding care in the sun. • Check FBC, eGFR, ALT and albumin, BP and glucose, every 2 weeks, until a stable dose has been achieved for 6 weeks. • Patient to ensure disease is controlled and drug efficacy. • Watch creatinine if a NSAID is added (particularly diclofenac). GP prescribing responsibilities From six weeks after the stable dose has been commence...
Administration Information
